Recombinant Vesicular Stomatitis Virus Expressing Respiratory Syncytial Virus (RSV) Glycoproteins: RSV Fusion Protein Can Mediate Infection and Cell Fusion  by Kahn, Jeffrey S. et al.
s
t
f
v
s
s
v
v
a
f
r
1
e
p
p
c
r
e
e
s
i
G
V
J
A
P
S
Virology 254, 81–91 (1999)
Article ID viro.1998.9535, available online at http://www.idealibrary.com onRecombinant Vesicular Stomatitis Virus Expressing Respiratory Syncytial Virus (RSV)
Glycoproteins: RSV Fusion Protein Can Mediate Infection and Cell Fusion
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The genes encoding the respiratory syncytial virus (RSV) attachment (G) and fusion (F) envelope glycoproteins were
expressed separately as additional genes in recombinant vesicular stomatitis viruses (VSV). Cells infected with the VSV-RSV
F recombinant formed large syncytia illustrating the fusion activity of F in absence of other RSV proteins. Both F and G
glycoproteins were expressed at the cell surface and incorporated into virions. Incorporation of these proteins did not require
cytoplasmic tail sequences of VSV G. Using a compound, ammonium chloride, that raises the endosomal pH, we showed that
presence of the RSV F glycoprotein in the envelope of recombinant VSV allowed for infectivity through a low-pH-independent
pathway. Recombinant VSV expressing RSV glycoproteins could be useful as an RSV vaccine. © 1999 Academic Press
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(INTRODUCTION
Attachment and entry represent the first essential
teps of viral replication. Enveloped viruses have evolved
wo distinct pathways to mediate the entry into the in-
ected cell. The first, or low-pH-dependent pathway, in-
olves uptake of the attached viral particle into an endo-
ome or lysosome. Conformational changes of the viral
urface glycoprotein(s), induced by the mildly acidic en-
ironment of the endosome, trigger fusion between the
iral and endosomal lipid membranes. Membrane fusion
llows release of the nucleocapsid into the cytoplasm
ollowed by initiation of viral transcription and genome
eplication (Marsh and Helenius, 1980; Matlin et al.,
982). In the second pathway, direct fusion of the viral
nvelope with the plasma membrane occurs at neutral
H. The nucleocapsid is released directly into the cyto-
lasm after viral attachment and fusion of the viral and
ellular membranes (Lamb, 1993).
Rhabdoviruses are enveloped negative-strand RNA vi-
uses that are endocytosed and require acidification of the
ndosome for infectivity (White et al., 1981). This pathway of
ntry is called the low-pH-dependent pathway. Vesicular
tomatitis virus (VSV), the prototype rhabdovirus, contains
n its envelope a single species of a viral glycoprotein, VSV
, which is responsible for both attachment and entry into
1 Present address: The Dorrance H. Hamilton Center for Human
irology, Department of Biochemistry and Molecular Pharmacology,
efferson Medical College, Thomas Jefferson University, 329 Jefferson
lumni Hall, Philadelphia, PA 19107-6799.
2 To whom reprint requests should be addressed at Department of
athology, BML 342, Yale University School of Medicine, 310 Cedarwtreet, New Haven, CT 06510. E-mail: Jrose@biomed.med.yale.edu.
81he infected cell. Following attachment and endocytosis,
onformational changes of the VSV G occur in the acidic
icro-environment (pH , 6.1) of the endosome which likely
xposes a hydrophobic domain of the viral glycoprotein
Florkiewicz and Rose, 1984; Riedel et al., 1984; Zhang and
hosh, 1994; Fredericksen and Whitt, 1998). This domain is
hought to insert into the endosomal membrane and medi-
te fusion, leading to release of the nucleocapsid core into
he cytoplasm (Matlin et al., 1982). Conversely, respiratory
yncytial virus (RSV), a pneumovirus (family Paramyxoviri-
ae) can fuse at neutral pH directly with the cell membrane
Srinivasakumar et al., 1991). The viral envelope proteins
re then incorporated into the plasma membrane after
usion (Routledge et al., 1987). Attachment and fusion are
ediated by two viral glycoproteins, G and F, respectively.
he fusion properties of the RSV F glycoprotein are sup-
orted by three lines of evidence: (1) RSV F is related both
tructurally and functionally to the fusion proteins of other
aramyxoviruses (Collins et al., 1984, 1996; Spriggs et al.,
986), (2) monoclonal antibodies against RSV F inhibit fu-
ion in cell culture (Walsh and Hruska, 1983), and (3) ex-
ression of RSV F in recombinant SV40 results in syncytia
ormation (Olmsted et al., 1986). However, cell fusion and
yncytia formation appeared to require RSV G and the small
ydrophobic SH protein in addition to RSV F in the vaccinia
ransient expression system, indicating that these other
SV proteins have important accessory functions in fusion
Heminway et al., 1994). However, the role of the G and SH
roteins in RSV infectivity remains unclear because RSV
acking the SH (Bukreyev et al., 1997) or SH and G genes
Karron et al., 1997) are replication competent in cell culture.
In the studies reported here, we sought to determine
hether a VSV recombinant expressing the RSV F gly-
0042-6822/99 $30.00
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82 KAHN ET AL.oprotein would incorporate the F protein into the VSV
nvelope and then be able to enter cells via the low-pH-
ndependent pathway. Recent advances in the recovery
f negative-strand RNA viruses from cDNA now allow the
nsertion of foreign genes into VSV (Lawson et al., 1995;
chnell et al., 1996a). Both RSV F and G were cloned and
xpressed in recombinant VSV. Infectivity, with respect to
H-dependent penetration, of these recombinant viruses
s compared to wild-type VSV was assessed.
RESULTS
Our laboratory has previously described cloning and
xpression of foreign genes in recombinant vesicular
tomatitis viruses (Schnell et al., 1996a,b; Johnson et al.,
997; Kretzschmar et al., 1997). Recovery of infectious
ecombinants is based on the assembly of full-length
ntigenomic RNA into RNPs that act as a template for
eplication. Full-length antigenomic RNA containing ad-
itional genes is synthesized in vaccinia/T7-infected
ells also expressing the VSV N, P, and L proteins, and
NP assembly occurs within infected cells. In this
resent study, we describe derivation of VSV recombi-
FIG. 1. Genome location of the RSV glycoproteins genes in recombin
gene was cloned between the VSV-M and G genes, and the F glycopr
gene (F/GT) was also constructed. The carboxyl terminus (29 amino
xchanged for the cytoplasmic domain (carboxyl-terminal 24 amino aci
old) and the VSV G 39 nucleotide sequences and the carboxyl termin
rotein contains 550 amino acids of RSV F and 29 amino acids of VSVants expressing RSV F and G proteins and examine the siochemical properties and functional characteristics of
hese recombinant viruses in infected cells.
xpression of the RSV G and F genes from
ecombinant VSVs
Recombinant viruses expressing RSV glycoproteins
ere derived from a plasmid encoding the entire VSV
enome (Schnell et al., 1996b; Kretzschmar et al., 1997)
ith the RSV glycoprotein genes cloned at expression
ites containing appropriate transcription start/stop sig-
als (Fig 1). The RSV G gene was inserted between the
SV M and G genes, and the RSV F gene was cloned in
second construct between the VSV G and L genes.
oth recombinant viruses were recovered using a mod-
fication of published procedures (Schnell et al., 1996b;
retzschmar et al., 1997).
Initial screening of recombinant viruses expressing
he RSV glycoproteins was performed via immunofluo-
escence. Recovery supernatants (second passage)
ere used to infect BHK cells on coverslips. Cell-surface
mmunofluorescence was performed after detection of
ytopathic effects (8–12 h). As shown in Fig. 2a, expres-
. Wild-type VSV gene order is shown at the top of the figure. The RSV
ene was inserted between the VSV G and L genes. A hybrid RSV F/VSV
representing the cytoplasmic domain of the VSV G glycoprotein was
SV F. RSV F nucleotide and amino acid sequences (underlined and in
o acid sequences are shown at the bottom of the figure. The hybrid
e F/GT gene was cloned between VSV G and L.ant VSV
otein g
acids)
ds) of R
al aminion of RSV G at the surface of BHK cells was confirmed
u
c
e
p
R
n
C
V
e
o
i
p
c
s
B
s
G
r
i
I F is a
83RSV PROTEIN MEDIATIONsing a mouse anti-RSV G monoclonal antibody. Control
ells infected with VSV were negative for RSV G protein
xpression. Both wild-type and recombinant virus ex-
ressed the VSV G glycoprotein as expected.
Expression of RSV F in BHK cells infected with VSV-
SV F recombinant virus was also confirmed by immu-
ofluorescence (Fig. 2b) using mouse anti-RSV F mAb.
FIG. 2. Expression of RSV G and RSV F in recombinant VSV. (A) Indi
HK monolayers were infected at an m.o.i. of 10, and cells were fixed a
pecificity is indicated at the top (aVSV G represents two monoclonal an
is a mouse monoclonal against RSV G). Virus is indicated on the le
escence of VSV and VSV-RSV-F-infected BHK cells. BHK monolayer
mmunofluorescence at 8 h after infection. Monoclonal antibody speci
1and I14, which are specific for the G glycoprotein of VSV, and aRSVells infected with VSV-RSV F expressed both RSV F and hSV G on the cell surface while VSV-infected cells only
xpressed VSV G. The immunofluorescence micrograph
f VSV-RSV-F-infected cells also revealed that this virus
nduced drastically different cytopathic effects as com-
ared to wild-type virus-infected cells. The characteristic
ytopathic effect of cell rounding caused by VSV was
een in both wild-type- and VSV-RSV-G-infected cells,
rface immunofluorescence of VSV and VSV-RSV-G-infected BHK cells.
ened by immunofluorescence 8 h after infection. Monoclonal antibody
s, I1 and I14, which are specific for the G glycoprotein of VSV and aRSV
xpression of RSV F in recombinant VSV. Indirect surface immunofluo-
infected with a m.o.i. of 10, and cells were fixed and screened by
indicated at the top (aVSV G represents two monoclonal antibodies,
mouse monoclonal against RSV F). Virus is indicated on the left.rect su
nd scre
tibodie
ft. (B) E
s were
ficity isowever, the VSV-RSV F recombinant virus induced syn-
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84 KAHN ET AL.ytia formation and cell fusion. This phenomenon is
llustrated more clearly in photomicrographs of wild-type
nd recombinant virus-infected cells (Fig 3). This finding
upports the hypothesis that RSV F expression is able to
ause cell–cell fusion in the absence of other RSV pro-
eins.
etection of RSV G proteins in cell lysates and
iruses
In RSV infection, the RSV G protein is heavily glycosy-
ated with O- and N-linked glycans increasing its appar-
nt molecular weight from 32.6 to ;90 kDa (Wertz et al.,
989; Collins and Mottet, 1992). To determine the appar-
nt molecular weight of RSV G expressed from the VSV-
SV G recombinant, lysates from infected cells were
xamined by immunoblotting. Figure 4 shows that RSV G
resent in lysates from VSV-RSV-G-infected cells ap-
eared as a broad smear around 90 kDa. Also noted in
ysates is a band (.33 kDa) and a higher molecular
FIG. 3. VSV-RSV F causes syncytia formation. Virus-induced cyto
onolayers were infected with virus at a m.o.i. of 10. Photographs of ph
nduced by VSV (B) and VSV-RSV G (C) and syncytia mediated by VSVeight smear. These likely represent G with various fegrees of addition or processing of N- and O-linked
lycans. This migration is similar to that of RSV G in
SV-infected HEp-2 cells (data not shown). We also ob-
erved incorporation of RSV G glycoprotein into purified
SV-RSV G recombinant virions (Fig. 4). Because the
ajority of RSV G incorporated into virions appears to be
f higher molecular weight, this presumably represents
rotein that has been fully processed after passage
hrough the Golgi apparatus and is then on the surface of
he cell where it can be incorporated.
SV F is incorporated into recombinant virions with
r without the VSV G cytoplasmic tail
To determine whether the RSV F glycoprotein would
llow for VSV infectivity through a neutral pH pathway, it
as first necessary to determine whether RSV F protein
as incorporated into recombinant virions. Metabolic
abeling with [35S]methionine was performed on VSV and
SV-RSV-F-infected cells, and harvested virus was puri-
effects are shown in the photomicrographs above. Confluent BHK
ntrast microscopy (325) were taken 10 h after infection. Cell rounding
(D) are shown. Uninfected cells are shown in (A).pathic
ase coied and concentrated. Immunoprecipitation of purified
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85RSV PROTEIN MEDIATIONabeled virus, using a goat anti-RSV polyclonal antibody
onfirmed the presence of the 48- (F1) and 20- (F2) kDa
ubunits of the RSV F glycoprotein (Fig. 5).
Our laboratory has previously demonstrated a require-
ent for the VSV G glycoprotein cytoplasmic domain for
fficient incorporation of HIV env protein into virions
Owens and Rose, 1993; Johnson et al., 1997; Schnell et
l., 1998) although several other proteins did not require
he tail for incorporation (Schnell et al., 1996a;
retzschmar et al., 1997). We therefore sought to deter-
ine whether the presence of the cytoplasmic tail of the
SV G glycoprotein would enhance incorporation of the
SV F glycoprotein into recombinant virions. The cyto-
lasmic domain of the RSV F glycoprotein (the 24 car-
oxyl terminal amino acids) was exchanged for the cy-
oplasmic tail of VSV G (29 amino acids). Recombinant
irus (VSV-RSV F/GT) encoding this hybrid glycoprotein
as obtained, and expression of the RSV F/GT protein
as confirmed by immunofluorescence and by immuno-
reciptiation of cell lysates (data not shown). Immuno-
recipitation of metabolically labeled, purified VSV-RSV
/GT proteins was compared to VSV-RSV F (Fig. 5). Equal
mounts of labeled protein were used for each immuno-
recipitation, and each reaction was performed in anti-
ody excess. The RSV F/GT was incorporated into re-
ombinant virions and cleaved into F1 and F2 domains.
he differences in the length of the carboxylterminus
FIG. 4. RSV G is incorporated into recombinant VSV virions. Immu-
oblot of VSV- and VSV-RSVG-infected cell lysates and purified virus
re shown. Proteins from VSV- and VSV-RSV-G-infected cells and pu-
ified virus were separated through a 12% polyacrylamide (SDS) gel and
ransferred to nitrocellulose. Equal amounts of protein were added for
ach lysate or virus preparation. The blot was probed with goat anti-
SV serum and antibody binding detected with horse radish peroxi-
ase conjugated donkey anti-goat IgG. Position of molecular weight
akers are shown on the left. Cell lysate (L) and purified virus (V) lanes
re indicated; U is uninfected cell lysate.etween the RSV and RSV F/GT account for the slight lecrease in electrophoretic mobility of the F/GT F1 sub-
nit. Overexposure of the gel in Fig. 5 revealed that the
ands present in lanes 2 and 3, other than F1 (F/GT1) and
2 were present in the VSV sample (lane 1). The pres-
nce of VSV proteins is explained by nonspecific binding
f the RSV antibody and incomplete disruption of the viral
articles during the immunoprecipitation. Quantification,
y phosphoimager analysis, did not reveal a significant
ifference in intensity of the F1 bands. Therefore the
ytoplasmic domain of the VSV G glycoprotein did not
nhance RSV F incorporation into recombinant virions.
dditional sequences of VSV G protein or display of the
tail in another context might be required to enhance
ncorporation.
It is thought that the virion spikes of RSV consist of
etramers composed of two dimers of the F glycoprotein.
he RSV F migrates as a 140-kDa dimer on SDS–PAGE
ithout reducing agent (Walsh et al., 1986). To determine
hether the RSV F protein synthesized in VSV-RSV-F-
nfected cells was present as a dimer, both infected cell
ysates and purified virus proteins were separated by
DS–PAGE without reduction and analyzed by Western
lotting using an anti-RSV polyclonal antibody. As shown
n Fig. 6, a 140-kDa band is present in virions of VSV-RSV
and VSV-RSV F/GT, lanes 3 and 4, respectively, but not
FIG. 5. Incorporation of RSV F and F/GT in recombinant VSV virions.
roteins of metabolically labeled ([35S]methionine), purified virus were
mmunprecipitated with a polyclonal antiserum against RSV and frac-
ionated by SDS–PAGE. Equal amounts of labeled virus were used for
ach immunoprecipitation. Labeled virus (prior to immunoprecipitation)
re run in parallel. Positions of the VSV proteins are indicated on the
eft. The position of the RSV F and F/GT (F1 domains) and the F2
omains of the viral glycoprotein are indicated on the right of the figure.
mages of labeled proteins were generated by a Phosphoimager (Mo-
ecular Dynamics).
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86 KAHN ET AL.n the VSV control (lane 2). This band comigrates with
SV F from lysates of RSV-infected HEp-2 cells (lane 1).
his 140-kDa band represents the dimeric form of the
SV F glycoprotein, and the VSV G cytoplasmic tail does
ot interfere with dimer formation (lane 4).
SV-RSV F infection can be mediated by RSV F
VSV infectivity requires the attachment of the G glyco-
rotein to a cell surface receptor followed by endocytosis
FIG. 6. Western blot analysis of VSV-RSV F and VSV-RSV F/GT viral
roteins. Purified virion proteins were treated with SDS at 21°C (without
educing agents) and separated by 10% SDS–PAGE. Proteins were
ransferred to nitrocellulose, probed with a goat anti-RSV antiserum,
nd visualized with horse radish peroxidase conjugated donkey anti-
oat IgG. Lane 1, RSV (HEp-2-infected cell lysate); lane 2, VSV; lane 3,
SV-RSV F; lane 4, VSV-RSV F/GT. Position of molecular weight makers
re shown on the left.
FIG. 7. VSV infectivity via a pH-independent pathway is mediated by R
bsence (a–c) and presence (d–f) of ammonium chloride is shown. H
SV-RSV F (c and f) at a m.o.i. of 0.5 with or without ammonium chloride.
or an additional 24 h. Subsequently, the cells were fixed, and VSV
ntiserum against VSV and a secondary rhodamine-conjugated goat anti rabMatlin et al., 1982). The low pH of the endosome causes
conformational change in the VSV G glycoprotein that
llows for fusion of the lysosomal membrane and viral
nvelope leading to viral uncoating (Matlin et al., 1982;
idelman et al., 1984; Florkiewicz and Rose, 1984; Riedel
t al., 1984). Lysosomotroptric agents that raise the en-
osomal pH block VSV infectivity (Matlin et al., 1982).
SV infection, on the other hand, is mediated by direct
usion of the viral envelope and cell membranes (pre-
umably by the F glycoprotein) thereby not requiring
irect endocytosis (Srinivasakumar et al., 1991). We were
nterested whether the presence of RSV F in recombinant
SV virions would allow infection via fusion at the cell
urface. VSV, VSV-RSV G, and VSV-RSV F viruses were
sed to infect HEp-2 cells in the absence and presence
f 10 mM ammonium chloride. The HEp-2 cell line was
hosen for two reasons, (1) this cell line supports the
rowth of RSV and (2) ammonium chloride blocks VSV
nfectivity but not RSV infectivity in HEp-2 cells (Sriniva-
akumar et al., 1991). HEp-2 cells were pretreated for 1 h
ith ammonium chloride, infected with virus at an m.o.i.
f 0.5, and incubated for an additional 24 h in the pres-
nce of the drug. The ammonium chloride was washed
way, and 24 h later the infected cells were screened by
F, and supernants of infected cells were collected for
itration. The immunofluorescence shown in Fig. 7 re-
ealed the infectivity of the VSV-RSV F in the presence of
mmonium chloride (Fig. 7f). RSV-infected HEp-2 cells
with ammonium chloride treatment) were also positive
y immunofluorescence (data not shown). Virtually no
mmunofluorescence signal was detected in the VSV-
munofluorescence of VSV and recombinant virus-infected cells in the
lls were infected with either VSV (a and d), VSV-RSV G (b and e) or
p.i., the drug was washed away and the infected cells were incubated
s were detected via immunofluorescence using a rabbit polyclonalSV F. Im
Ep-2 ce
At 24 h
proteinbit IgG. Magnification is 340.
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87RSV PROTEIN MEDIATIONnd VSV-RSV-G-infected cells in the presence of ammo-
ium chloride (Figs. 7d and 7e, respectively). Control
nfections (without ammonium chloride) with all three
iruses were all positive for infectivity (Figs. 7a–7c). Ti-
ration of supernants from infected cells confirmed the
mmunofluorescence finding. Each virus produced equiv-
lent titers in the absence of the drug yet only VSV-RSV
propagated in the presence of ammonium chloride
Table 1). In infected cell cultures treated with ammonium
hloride, the RSV F recombinant yielded viral titers two
rders of magnitude greater than the VSV or VSV-RSV G
iruses. However, the presence of RSV F, but not RSV G,
n recombinant VSV virions allows for infection through
usion of the viral envelope and the cell membrane.
DISCUSSION
We describe here evidence that a recombinant rhab-
ovirus encoding a paramyxovirus fusion protein can
nter an infected cell through a pathway that does not
equire acidification of endosomes. The fusion protein of
SV, a paramyxovirus, was cloned and expressed in
ecombinant VSV-infected cells. Biochemical evidence
emonstrated that the RSV F glycoprotein was incorpo-
ated into virions, and functional studies revealed that
he presence of this glycoprotein in the viral envelope
llowed for infectivity that was independent of endosome
cidification. This low-pH-independent infectivity was
pecific to the RSV F protein since expression of RSV G
id not allow for pH-independent infectivity. Since the
ecovery of infectious VSV from cDNA by our laboratory,
e have engineered several viral envelope glycoproteins
n this rhabdovirus (Schnell et al., 1996a,b; Johnson et al.,
997; Kretzschmar et al., 1997). VSV (HIV) pseudotypes
Dalgleish et al., 1984) or recombinants expressing HIV
nv (Johnson et al., 1997) or CD4 and CXCR4 (Schnell et
l., 1997) presumably also enter through a low-pH-inde-
endent pathway although this has not been shown
TABLE 1
Effect of Ammonium Chloride on Viral Replicationa
Virus
(2)
Ammonium
chloride
Ammonium
chloride
(10 mM)
SV 3.0–7.0 3 106 2.0–5.0 3 103
SV-RSV G 1.0–4.0 3 106 2.0–3.8 3 103
SV-RSV F 3.0–4.0 3 106 3.0–8.0 3 105
Note. Viral (pfu/ml) titers were performed in triplicate; figures repre-
ent the range titer for each sample.
a HEp-2 cells were infected with each virus at a m.o.i. of 0.5 in the
bsence or presence of ammonium chloride. The drug was washed
way at 24 h p.i. and supernatants from each infection were collected
t 48 h p.i. and subsequently titered.sing lysosomotropic agents. RExpression of RSV F in cells infected with recombinant
SV was also shown to be sufficient for cell–cell fusion.
ur results support the unpublished results of Olmstead
t al. (1986) that expression of RSV F in SV40 induces cell
usion. However, our findings are in contrast to the re-
ults of Heminway et al. (1994) that demonstrated that in
he vaccinia T7 transient expression system, RSV G and
H are also required for syncytia formation. One possible
xplanation for this discrepancy is that the VSV G glyco-
rotein replaces an attachment function of the RSV G
nd, perhaps, the SH protein. Infectivity of the VSV-RSV F
ecombinant virus was blocked by antibody against VSV
(data not shown). However, the lack of the requirement
f the RSV G and SH functions for membrane fusion is
lso supported by recent findings in recombinant and
old passaged RSV (Bukreyev et al., 1997; Karron et al.,
997). These viruses, which contain deletions of the SH
r G and SH genes, propagate efficiently and are phe-
otypically similar to wild-type virus.
The potential of these VSV recombinant viruses ex-
ressing the RSV envelope glycoproteins as vaccines is
urrently being evaluated. At this time there are no avail-
ble vaccines for RSV, the major respiratory infection of
nfants and children. Recombinant VSVs expressing for-
ign antigens have been shown recently to elicit protec-
ive immunity in experimental animals. Vaccination of
ice with recombinant VSV expressing the influenza
emagglutinin provides complete protection from influ-
nza challenge (Roberts et al., 1998). The VSV system
as many potential advantages over other viral-based
trategies for eliciting immunity against RSV. The single
nvelope glycoprotein of VSV offers significantly less
ntigenic background than the recombinant vaccinia vi-
us expressing RSV F (Olmsted et al., 1986) and G
Elango et al., 1986). In addition, the presence of F and G
n the virion envelope might provide better induction of
umoral immunity.
The potential of an inactivated recombinant VSV as a
accine against RSV is supported by the presence of the
and G glycoproteins in the recombinant VSV envelope.
purified RSV fusion protein subunit vaccine elicits an
mmune response in human volunteers (Groothuis et al.,
998). Chemical inactivation may not be appropriate be-
ause an earlier Formalin-inactivated RSV vaccine actu-
lly enhanced natural infection (Kapikian et al., 1969);
owever, other means of inactivation are possible.
In this current study, we demonstrated that RSV enve-
ope glycoproteins can be efficiently expressed in recom-
inant VSV. The RSV F glycoprotein induced cell–cell
usion and allowed for infectivity through viral envelope–
lasma membrane fusion. The RSV G glycoprotein was
lycosylated properly and also incorporated into virions.
hese findings support the investigation of recombinant
SV as a potential RSV vaccine and a means to study
SV immunopathogenesis.
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88 KAHN ET AL.MATERIALS AND METHODS
ells and viruses
Baby hamster kidney cells (BHK-21, American Type
issue Collection) and human larynx carcinoma cells
HEp-2, American Type Tissue Collection) were main-
ained in Dulbecco’s minimal essential media (DMEM)
upplemented with 5 or 10% fetal bovine serum (FBS),
espectively. RSV A2 (supplied by Peter Collins, National
nstitutes of Health) was propagated on HEp-2 cells.
ubconfluent monolayers (70%) were infected with RSV
t a m.o.i. of 0.01. Virus was prepared at 3 days p.i. (80%
yncytium formation) using a modification of the tech-
ique described elsewhere (Srinivasakumar et al., 1991).
Working stocks of VSV and recombinant virus were
repared as follows. Monolayers of BHK cells (80% con-
luent) on 100-mm plates were infected with virus at
.o.i. of 0.01. After 18–24 h, supernatants were collected
nd cellular debris removed by low-speed centrifugation.
oncentration and purification of virus were achieved by
ltracentrifugation of viral stock solutions through a 10%
ucrose solution (38,000 rpm, Beckman SW41 rotor, 4°C,
h).
onstruction of RSV-VSV plasmids
Two separate plasmid vectors were used to clone the
SV F and RSV G genes into the full-length VSV genome.
he plasmids, which contain sites for foreign gene in-
ertion at different intergenic junctions, express the pos-
tive-strand complement of the viral genome. The inter-
enic cloning sites are flanked by appropriate transcrip-
ion start/stop signals for expression of foreign genes.
RSV F was cloned into the full-length VSV vector pVSV-
N1, described previously (Schnell et al., 1996b). This
lasmid contains the five VSV genes (N, P, M, G, and L)
n order flanked by the bacteriophage T7 promoter VSV
eader and the ribozyme and T7 terminator sequences.
nique restriction sites (XhoI and NheI) are positioned
etween the G and L genes. PCR amplification of the
SV F gene was as follows. PCR primers were synthe-
ized to allow rapid directional cloning of the RSV F gene
nto pVSV-XN1. The forward primer, 59-ATCTCCCCCGG-
CTCGAGACAATGGAGTTGCTAATCC contained unique
hoI site (bold-face letters) and the initial 16 bases of the
SV F gene coding sequences (underlined) (Collins et
l., 1984); the reverse primer, 59-GCATAAGAATGCGGCC-
CGCTAGCTTAGTTACTAAATGCAATAT included unique
heI site (bold face letters) and the last 20 bases of the
SV F coding sequences (underlined letters). Total RNA
rom RSV-infected HEp-2 cells (3 days p.i.) was isolated
TRIzol method, Gibco BRL) and used as substrate for
everse transcriptase (RT) reactions. Reverse transcrip-
ion (M-MuLV Reverse transcriptase, New England Bio-
abs) of the purified RNA with the reverse primer was
ollowed by high-fidelity PCR with VENT polymerase vNew England Biolabs) with both primers. The RSV F
CR product was digested with XhoI and NheI and
loned into the pVSV-XN1 vector. Ligations, bacterial
ransformations, and plasmid preparations were per-
ormed using standard protocols (Sambrook et al., 1989).
RSV G was cloned into the full-length VSV cloning
ector pVSVMXA (Kretzschmar et al., 1997). This plasmid
s similar to pVSV-XN1 except that the intergenic cloning
ite with transcriptional signals is between the M and G
enes and the unique restriction sites are MluI and XbaI.
CR primers were synthesized to allow rapid directional
loning of the RSV G gene into pVSV-MXA. The forward
rimer, 59CTCGCTCGAGACGCGTAACATGTCCAAAAAC-
AGGACC contained unique MluI site (bold-face letters)
nd the initial 19 bases of the RSV G gene (underlined)
Wertz et al., 1985); the reverse primer, 59AGCTCGC-
AGCCCCGGGCTACTGGCGTGTTGTGTTGGG included
nique XbaI site (bold face letters) and the last 21 bases
f the RSV G gene (underlined letters). RSV RNA purifi-
ation, reverse transcription, and PCR were performed
s described above. The RSV G PCR product was di-
ested with MluI and XbaI and cloned into the pVSVMXA
ector.
The RSV F gene containing the VSV G tail (F/GT), in
hich the sequences encoding the 24 carboxyl-terminal
mino acids of RSV F was replaced by the sequences
ncoding the 29 carboxyl-terminal amino acid tail of the
SV G glycoprotein was constructed as follows. The VSV
tail sequences were amplified with PCR. The forward
rimer, 59GTTGGACTGCTCTTATACTGTCGAGTTGGTAT-
CATCT TTGC contains the 21 nucleotides (underlined)
mmediately upstream of the sequences encoding the 24
OOH amino acids of the RSV F gene (Collins et al.,
984) followed by the 59 21 nucleotides of the VSV G tail
equence. The reverse primer, 59 ACGTACGTGCTAGCT-
ACTTTCCAAGTCGGTTC contains the 39 19 nucleotide
oding sequence and stop codon (underlined) of VSV G.
n NheI site is indicated by bold letters. The product of
his PCR reaction (21 bp of RSV F sequence followed by
he VSV G tail sequence) was used to prime synthesis on
he RSV F gene. The F/GT gene was then amplified by
CR using the reverse primer (above) starting in the G
ail sequences and the forward primer used to amplify
he F gene (above). The resulting DNA fragment, F/GT,
as cloned into pVSV-XN1 using XhoI and NheI.
Full-length genomic VSV plasmids containing the RSV
enes and the other support plasmids for the transfec-
ions (pBS-N, pBS-P, pBS-L) were propagated and pre-
ared in Escherichia coli strains C600 and DH5 (alpha).
ransfections and recovery of recombinant VSV virus
Recovery of recombinant VSV has been described
reviously (Lawson et al., 1995; Schnell et al., 1996b).
riefly, BHK cells were infected at a m.o.i. of 10 with
accinia virus expressing the T7 phage polymerase. At
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89RSV PROTEIN MEDIATIONh p.i., the cells were transfected with separate plas-
ids containing the nucleocapsid and RNA polymerase
enes VSV-N, P, L, under T7 promoter in addition to the
lasmids containing the full-length VSV genome and the
SV gene. Hydroxyurea (HU) was added to the transfec-
ions to limit the vaccinia virus replication and DNA
ecombination (Slabaugh and Mathews, 1986). VSV rep-
ication is not inhibited by HU (unpublished results). The
ransfection solutions were removed after 3 h and re-
laced with DMEM with 5% FBS. After 2 days, transfec-
ion supernatants were filtered (0.22 mm) to remove re-
idual vaccinia virus and then passaged twice on unin-
ected BHK cells in the presence of HU. Supernatants
rom the second virus passage were used to infect BHK
ells on coverslips, and immunofluorescence (surface
abeling) was performed after detection of cytopathic
ffects (8–12 h). After confirmation of RSV gene express
y immunofluorescence, the viral strains were propa-
ated as described above.
mmunofluorescence microscopy
Infected cell monolayers were fixed with 3% parafor-
aldehyde and stained with either the monoclonal anti-
odies (mAB) I1 I14 against the VSV G glycoprotein
Lefrancois and Lyles, 1982) or a mAB against RSV F of G
Chemicon International, Inc.) or goat anti-RSV antisera
Virostat) followed by fluorescein isothiocyante-conju-
ated goat anti-mouse antibody or donkey anti-goat an-
ibody (Jackson Research). Fixed cells were examined by
ndirect immunofluorescence with a Nikon Microphot-FX
icroscope equipped with a 340 planapochromat ob-
ective.
etabolic labeling and immunoprecipitation
For metabolic labeling of cellular and virion proteins,
early confluent BHK cell monolayers (3.5-cm plates)
ere infected with wild-type or recombinant VSV at a
.o.i. of 20. At 4 h p.i., cells were washed with methi-
nine-free DMEM media and then labeled with 100 mCi
35S]methionine (New England Nuclear) in DMEM, 3%
BS. Cell lysates were prepared after 2 h of metabolic
abeling. Monolayers were washed with PBS and then
ncubated at 4°C with detergent solution (1% Nonidet-
40, 0.4% deoxycholic acid, 66 mM EDTA, 10 mM Tris–
Cl, pH 7.4) for 5 min. Lysates were centrifuged to
emove nuclei and cellular debris, and supernatants
ere used for protein gel electrophoresis analysis and
mmunoprecipitation. Labeled virion proteins were pre-
ared following 16 h of metabolic labeling. Supernatants
f infected monolayers were collected, and cell debris
as removed from the media with low speed centrifuga-
ion (1250 g, 5 min). Virus was pelleted from supernatants
hrough sucrose as described above. Virus pellets were
esuspended in 10 mM Tris–HCl, pH 7.6 and analyzed
ith SDS–PAGE (denaturing and reducing conditions). sabeled proteins were detected with a Phosphorimager
Molecular Dynamics).
Immunoprecipitations of labeled cellular and virion
roteins were performed with antiserum against dena-
ured, reduced RSV virions (supplied by Peter Collins,
IH). Cell lysate or virions were precleared by incubation
ith Staphylococcus aureus (Pansorbin, Calbiochem) at
7°C for 15 min in detergent solution with 0.1% SDS.
abeled preparations were incubated with antiserum at
7°C for 30 min after which S. aureus was added for an
dditional 30 min. Immunocomplexes were pelleted by
entrifugation (10,000 g, 2 min) and washed three times
n RIPA buffer (1% Nonidet-P40, 1% deoxycholic acid, 0.1%
DS, 150 mM NaCl, 10 mM Tris–HCl, pH 7.4) before
DS–PAGE.
estern blot analysis
Cellular and viral proteins were subjected to electro-
horesis through a 10% SDS–polyacrylamide gel and
ransferred to a nitrocellulose filter (Amersham) as de-
cribed elsewhere (Sambrook et al., 1989). Subsequently
he filter was dried, blocked in 5% blotto (Carnation
onfat milk in PBS) and incubated with the primary anti-
era at a dilution of 1:250 in blotto overnight at room
emperature. After multiple washes in PBS, the filter was
ncubated with the secondary antibody (horse radish
eroxidase conjugated donkey anti rabbit, Jackson Im-
unoresearch Laboratories) at a dilution of 1:1000 in 150
M NaCl, 50 mM Tris–HCl, pH 7.6). The filter was
ashed in 150 mM NaCl, 50 mM Tris–HCl, pH 7.6 and
eroxidase activity was detected with DAB substrate
Sigma).
mmonium chloride inhibition assays
HEp-2 cells (80% confluent, on 35-mm plates with
overslips) were pretreated 1 h prior to infection with
mmonium chloride, final concentration of 10 mM. The
ells were infected with an m.o.i. of 0.5 in the presence
f 10 mM ammonium chloride. After 1 h, the inoculum
as removed and the cells washed three times with
MEM containing 10 mM ammonium chloride to remove
ny residual virus. The cells were incubated for 24 h with
edia containing 10% FBS and 10 mM ammonium chlo-
ide. Subsequently, the compound was washed away,
nd the cells were incubated in DMEM and 10% FBS.
fter 24 h, supernatants were collected, cleared of cell
ebris by centrifugation and titered. Viral infection was
onitored by immunofluorescence assays performed on
ells fixed on the coverslips.
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